The FDA's Commissioner's National Priority Voucher (CNPV) program, designed to expedite drug reviews for national health priorities, is under scrutiny as questions mount over its opaque selection process and the dominance of large pharmaceutical recipients.
Three high-profile FDA rejections—involving priority vouchers, rare disease therapies, and transparency policies—reveal an agency in flux, creating new uncertainties for the pharmaceutical industry.
The U.S. FDA has declined to grant accelerated approval for Disc Medicine's bitopertin, a potential treatment for erythropoietic protoporphyria (EPP), citing insufficient evidence linking a key biomarker reduction to tangible patient benefits. The company now pins its hopes on a larger ongoing trial, potentially pushing a final decision to 2027.
In a significant setback for Moderna, the U.S. Food and Drug Administration has refused to accept for review the company's application for its mRNA-based influenza vaccine, mRNA-1010. Moderna contends the decision contradicts prior agency feedback and established flu vaccine guidelines.
The dietary supplement industry is urging the FDA to reinterpret decades-old regulations, potentially allowing peptides, novel probiotics, and other non-traditional substances into consumer products. The push comes amid a shifting regulatory landscape and could significantly expand the $50 billion market.
The FDA vows swift action against the mass marketing of unapproved 'copycat' drugs, following telehealth provider Hims & Hers' launch of a compounded version of Novo Nordisk's Wegovy. The move reignites a fierce regulatory and legal battle over patient safety, drug access, and market competition in the booming weight-loss drug sector.
The U.S. FDA has issued a complete response letter for RGX-121, a gene therapy for ultra-rare Hunter syndrome, citing concerns over study design and endpoints. REGENXBIO plans to request an urgent meeting to discuss a path forward.
While a full market withdrawal of mRNA vaccines is unlikely, the FDA's recent actions—including a contentious reversal on Moderna's flu shot application—signal a tougher, more unpredictable approval pathway that is already chilling investment and innovation in the field.
In a notable regulatory shift, the FDA will now review Moderna's application for its experimental mRNA-based influenza vaccine, mRNA-1010, following a high-level meeting. The agency had rejected the filing just last week.
The U.S. Food and Drug Administration has rejected Regenxbio's gene therapy for Hunter syndrome, marking the latest in a series of regulatory setbacks for the sector and raising questions about the agency's evolving stance on accelerated pathways for rare disease treatments.
After a second FDA rejection for its cell therapy Ebvallo, Pierre Fabre has requested an urgent 'Type A' meeting with regulators, highlighting the growing tension between drugmakers and the agency over shifting standards for rare disease treatments.
A regulatory chill is sweeping through the rare disease drug development sector as the FDA tightens its accelerated approval standards, leaving investors scrambling and companies facing unexpected hurdles.
In a bold move, Prime Medicine plans to seek accelerated approval for its ultra-rare disease gene therapy based on data from just two patients, challenging the FDA's recent pledges to streamline pathways for innovative treatments.
In a significant setback for UniQure, the U.S. Food and Drug Administration has insisted the company conduct a new randomized, sham-surgery-controlled trial before considering approval of its Huntington's disease gene therapy AMT-130, contradicting earlier discussions and sending the biotech's shares plunging.
Shares of gene therapy developers, led by UniQure, rallied Monday following the announced departure of FDA official Vinay Prasad, whose tenure was marked by heightened regulatory scrutiny and uncertainty for rare disease treatments.
Comments by FDA Commissioner Martin Makary during a televised interview triggered a sharp decline in UniQure's stock, as investors feared his critique of a specific therapy delivery method was a veiled reference to the company's flagship program for Huntington's disease.
Moderna's stock tumbled after U.S. regulators refused to even review its application for a novel mRNA-based seasonal flu vaccine, citing issues with its clinical trial design. The setback highlights the evolving regulatory landscape for next-generation vaccines.
A legal threat from Novo Nordisk forced telehealth provider Hims & Hers to withdraw a compounded version of its blockbuster weight-loss drug Wegovy. The move coincides with an FDA crackdown, spotlighting the intensifying battle over the lucrative but tightly regulated obesity treatment market.
A senior FDA official has stated that UniQure's recent trial for its Huntington's disease gene therapy failed to provide conclusive evidence of slowing the disease, defending the agency's request for a new, placebo-controlled study. The decision has sent the company's shares tumbling and sparked debate over regulatory standards for rare disease treatments.
In a significant turnaround, the U.S. FDA will now evaluate Moderna's modified mRNA influenza vaccine for adults, just a week after initially declining to review the application, sending the company's shares higher.
